| Autor: |
Selby, P., Blake, S., Mbidde, E.K., Hickmott, E., Powles, R.L., Stolle, K., Mcelwain, T.J., Whiteman, P.D., Fiddian, A.P. |
| Zdroj: |
The Lancet; December 1984, Vol. 324 Issue: 8417-8418 p1428-1430, 3p |
| Abstrakt: |
Acyclovir is an effective treatment for herpes simplex and herpes zoster infections, but it is somewhat limited by low oral absorption. 2-amino-9-[(2hydroxyethoxy)methyl]-9H-purine (BW A515U), a new prodrug of acyclovir, when evaluated in 10 patients with haematological malignancies, was well tolerated, excellently absorbed, and produced high plasma concentrations of acyclovir which were comparable to those with intravenous acyclovir. The plasma concentrations after oral BW A515U were much higher than those after oral acyclovir. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
